| Name | Title | Contact Details |
|---|
Canadian Hospital Specialties Ltd is a Oakville, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery` diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology` services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 65`000 employees have a passion and commitment to help improve patient outcomes` improve the safety and efficiency of clinicians` care delivery process` enable laboratory scientists to better diagnose disease and advance researchers’ capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers` BD can help enhance outcomes` lower costs` increase efficiencies` improve safety and expand access to health care. In 2017` BD welcomed C. R. Bard and its products into the BD family.
Wicab is a Middleton, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Ablative Solutions is a clinical-stage medical device start-up that is pioneering the novel approach of Transcatheter Perivascular Alcohol Denervation for the treatment of hypertension.
OXiGENE is a biopharmaceutical company developing new and improved therapeutics that have the potential to deliver significant medical benefits to patients with cancer and serious medical conditions. Our primary focus is developing first-in-class anti-vascular drugs referred to as vascular disrupting agents (VDAs). Our lead compound in clinical development is fosbretabulin. VDAs are a new and highly differentiated class of anti-vascular drug that target existing tumor vasculature, leading to extensive tumor cell death. VDAs target the tumor vasculature rather than the tumor cells and therefore have broad potential therapeutic utility in cancer. Because VDAs act differently than anti-angiogenic drugs or cytotoxic chemotherapy drugs, VDAs are potentially complementary with anti-angiogenic drugs and chemotherapeutic agents. OXiGENE has ongoing VDA drug development programs and is committed to advancing the science of VDAs and their potential as innovative therapies to address unmet medical needs.